{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:51:42Z","timestamp":1761519102962,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.clbc.2014.09.007","type":"journal-article","created":{"date-parts":[[2014,10,3]],"date-time":"2014-10-03T18:27:28Z","timestamp":1412360848000},"page":"251-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Neoadjuvant Ixabepilone\/Carboplatin\/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute"],"prefix":"10.1016","volume":"15","author":[{"given":"Denise A.","family":"Yardley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Zubkus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice F.","family":"Eakle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca G.","family":"Bechhold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey","family":"Finney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davey","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooke","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Hainsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2014.09.007_bib1","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1200\/JCO.2005.02.6187","article-title":"Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update","volume":"24","author":"Kaufmann","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib2","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.1999.17.2.460","article-title":"Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy","volume":"17","author":"Kuerer","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib3","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib4","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.1999.17.11.3412","article-title":"Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer","volume":"17","author":"Buzdar","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib5","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1200\/JCO.1999.17.10.3033","article-title":"Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group","volume":"17","author":"Miller","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3816\/CBC.2004.n.035","article-title":"Neoadjuvant FEC 100 for operable breast cancer: eight-year experience at Centre Jean Perrin","volume":"5","author":"Mouret-Reynier","year":"2004","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2014.09.007_bib7","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1200\/JCO.2005.06.232","article-title":"Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks","volume":"23","author":"Green","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib8","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1200\/JCO.2006.09.1777","article-title":"Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14","volume":"25","author":"Steger","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib9","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2005.06.156","article-title":"Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group study","volume":"23","author":"Evans","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib10","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","article-title":"Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer","volume":"23","author":"Buzdar","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1158\/1078-0432.CCR-06-1345","volume":"13","author":"Buzdar","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2014.09.007_bib12","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1200\/JCO.2006.09.9994","article-title":"Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial","volume":"25","author":"Coudert","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib13","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.22895","article-title":"Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M.D. Anderson experience","volume":"110","author":"Dawood","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2014.09.007_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3816\/CBC.2010.n.005","article-title":"Pathologic complete response to preoperative sequential doxorubicin\/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II\/III HER2-positive breast cancer","volume":"10","author":"Chumsri","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2014.09.007_bib15","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","article-title":"Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study","volume":"28","author":"Untch","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib16","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","article-title":"Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2\u2013overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups","volume":"29","author":"Untch","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1200\/JCO.2010.28.6450","volume":"29","author":"Valero","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib18","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2014.09.007_bib19","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00280-013-2140-y","article-title":"Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan","volume":"71","author":"Aogi","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clbc.2014.09.007_bib20","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1200\/JCO.2005.10.024","article-title":"Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer","volume":"23","author":"Low","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib21","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1200\/JCO.2006.09.3849","article-title":"Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine","volume":"25","author":"Perez","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib22","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1200\/JCO.2006.08.9102","article-title":"Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer","volume":"25","author":"Thomas","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib23","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.2006.10.0784","article-title":"Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes","volume":"25","author":"Denduluri","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib24","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1200\/JCO.2006.09.7535","article-title":"Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy","volume":"25","author":"Roche","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib25","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1200\/JCO.2009.24.4244","article-title":"Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"28","author":"Sparano","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib26","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1200\/JCO.2007.14.2646","article-title":"Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer","volume":"27","author":"Baselga","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib27","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10549-009-0658-9","article-title":"A\u00a0phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial","volume":"119","author":"Moulder","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2014.09.007_bib28","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.clbc.2014.09.007_bib29","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","article-title":"Effect of preoperative chemotherapy on the\u00a0outcome of women with operable breast cancer","volume":"16","author":"Fisher","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib30","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1200\/JCO.1998.16.1.93","article-title":"Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute","volume":"16","author":"Bonadonna","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib32","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib34","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1634\/theoncologist.2013-0075","article-title":"Neoadjuvant doxorubicin\/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of betaIII-tubulin expression as a predictive marker","volume":"18","author":"Saura","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2014.09.007_bib35","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10549-013-2552-8","article-title":"A\u00a0randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer","volume":"139","author":"Rugo","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2014.09.007_bib36","first-page":"1103","article-title":"TITAN: ixabepilone versus weekly paclitaxel following doxorubicin\/cyclophosphamide (AC) adjuvant chemotherapy in triple-negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial","volume":"29","author":"Yardley","year":"2011","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.clbc.2014.09.007_bib37","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1200\/JCO.2009.23.8303","article-title":"Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study","volume":"28","author":"von Minckwitz","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.09.007_bib38","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2003.05.135","volume":"21","author":"Therasse","year":"2003","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820914001992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820914001992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:14:35Z","timestamp":1761513275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820914001992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1526820914001992"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2014.09.007","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant Ixabepilone\/Carboplatin\/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2014.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}